A PHASE II TRIAL OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC WELL-DIFFERENTIATED DUODENO-PANCREATIC ENDOCRINE TUMORS (BETTER STUDY)

被引：0
|
作者：
Seitz, J. [1 ]
Smith, D. [2 ]
O'Toole, D. [3 ]
Lepere, C. [4 ]
Dromain, C. [5 ]
Gorana, A. [6 ]
Mitry, E. [7 ]
Ducreux, M. P. [8 ]
机构：
[1] Hop Enfants La Timone, Marseille, France
[2] Hop St Andre, Bordeaux, France
[3] Hop Beaujon, Clichy, France
[4] Hop Europeen Georges Pompidou, Paris, France
[5] Inst Gustave Roussy, Villejuif, France
[6] Labs Roche, Boulogne, France
[7] Inst Curie, Paris, France
[8] Inst Cancerol Gustave Roussy, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study)
    Ducreux, Michel
    Seitz, Jean-Francois
    Smith, Denis
    O'Toole, Dermot
    Lepere, Celine
    Bitoun, Laurence
    Mitry, Emmanuel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] A PHASE II TRIAL OF BEVACIZUMAB WITH CAPECITABINE IN PROGRESSIVE, METASTATIC WELL-DIFFERENTIATED DIGESTIVE ENDOCRINE TUMORS (BETTER STUDY)
    Walter, T. A.
    Baudin, E.
    Kurtz, J. E.
    Ruszniewski, P.
    Bengrine-Lefevre, L.
    Cadiot, G.
    Dominguez-Tinajero, S.
    Kraemer, S.
    Ducreux, M. P.
    Mitry, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 378 - 378
  • [3] Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
    Ducreux, Michel
    Dahan, Laetitia
    Smith, Denis
    O'Toole, Dermot
    Lepere, Celine
    Dromain, Clarisse
    Vilgrain, Valerie
    Baudin, Eric
    Lombard-Bohas, Catherine
    Scoazec, Jean-Yves
    Seitz, Jean-Francois
    Bitoun, Laurence
    Kone, Sebastien
    Mitry, Emmanuel
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3098 - 3106
  • [4] Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).
    Mitry, Emmanuel
    Walter, Thomas
    Baudin, Eric
    Kurtz, Jean-Emmanuel
    Ruszniewski, Philippe
    Dominguez, Sophie
    Bengrine-Lefevre, Leila
    Cadiot, Guilaume
    Kraemer, Sandrine
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
    Brixi-Benmansour, Hedia
    Jouve, Jean-Louis
    Mitry, Emmanuel
    Bonnetain, Franck
    Landi, Bruno
    Hentic, Olivia
    Bedenne, Laurent
    Cadiot, Guillaume
    DIGESTIVE AND LIVER DISEASE, 2011, 43 (11) : 912 - 916
  • [6] Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors
    Cheng, Yue-Juan
    Meng, Chang-Ting
    Ying, Hong-Yan
    Zhou, Jian-Feng
    Yan, Xiao-Yan
    Gao, Xin
    Zhou, Na
    Bai, Chun-Mei
    MEDICINE, 2018, 97 (45)
  • [7] Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    Ito, Tetsuhide
    Okusaka, Takuji
    Nishida, Toshirou
    Yamao, Kenji
    Igarashi, Hisato
    Morizane, Chigusa
    Kondo, Shunsuke
    Mizuno, Nobumasa
    Hara, Kazuo
    Sawaki, Akira
    Hashigaki, Satoshi
    Kimura, Nobuyuki
    Murakami, Mami
    Ohki, Emiko
    Chao, Richard C.
    Imamura, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1265 - 1274
  • [8] Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    Tetsuhide Ito
    Takuji Okusaka
    Toshirou Nishida
    Kenji Yamao
    Hisato Igarashi
    Chigusa Morizane
    Shunsuke Kondo
    Nobumasa Mizuno
    Kazuo Hara
    Akira Sawaki
    Satoshi Hashigaki
    Nobuyuki Kimura
    Mami Murakami
    Emiko Ohki
    Richard C. Chao
    Masayuki Imamura
    Investigational New Drugs, 2013, 31 : 1265 - 1274
  • [9] Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
    Ito, Tetsuhide
    Honma, Yoshitaka
    Hijioka, Susumu
    Kudo, Atsushi
    Fukutomi, Akira
    Nozaki, Akira
    Kimura, Yasutoshi
    Motoi, Fuyuhiko
    Isayama, Hiroyuki
    Komoto, Izumi
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 499 - 508
  • [10] Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
    Tetsuhide Ito
    Yoshitaka Honma
    Susumu Hijioka
    Atsushi Kudo
    Akira Fukutomi
    Akira Nozaki
    Yasutoshi Kimura
    Fuyuhiko Motoi
    Hiroyuki Isayama
    Izumi Komoto
    Seiichi Hisamatsu
    Akihiro Nakajima
    Akira Shimatsu
    Investigational New Drugs, 2017, 35 : 499 - 508
12345